COVIFOR- REMDESICIR 100MG VIAL
Remdesivir is an investigational nucleotide analog invented by Gilead, building on more than a decade of the company’s antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, SARS, Marburg, MERS and SARS-CoV-2, the virus that causes COVID-19.
Multiple ongoing international Phase 3 clinical trials are evaluating the safety and efficacy of Remdesivir for the treatment of COVID-19. Based on available data from these studies, Remdesivirhas been approved or authorized for temporary use as a COVID-19 treatment in approximately 50 countries worldwide. Additional ongoing international clinical trials continue to further evaluate the safety and efficacy of Remdesivir in different patient populations and formulations, and in combination with other therapies.